Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Copaxone Nears U.K. Approval, But NICE To Refuse MS Drug Payment

Executive Summary

Teva is expecting U.K. licensure of its multiple sclerosis drug Copaxone (glatiramer) in July for reduction in frequency of relapse in relapsing/remitting MS, the company indicated.

You may also be interested in...



Taxol And Taxotere Both Cleared For Routine Use After Bristol Appeal To U.K.

Both Bristol-Myers Squibb's Taxol and Aventis' Taxotere have been recommended for routine use by U.K.' s National Institute for Clinical Excellence for advanced second-line breast cancer treatment, following a successful appeal by Bristol.

Teva MS Success Helps Stock In Down Month: Biogen, Chiron Tumble

Teva's smooth performance in the multiple sclerosis market is shoring up the company in a difficult environment for biopharmaceutical stocks.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel